Updates are available Correction dated 2025-07-04

Article History

Received: 5 March 2025

Accepted: 26 May 2025

First Online: 7 June 2025

Change Date: 24 June 2025

Change Type: Update

Change Details: The original online version of this article was revised: The authors regret that the legends of the figures that appeared in the original published article are incorrect. The correct and incorrect figure legends are shown in the erratum article.

Change Details: The original article has been corrected.

Change Date: 4 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00259-025-07434-5

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki and was approved by the medical ethics review committee of the Amsterdam University Medical Center for ADC, the regional ethics committee at Lund University for BioFINDER-1, the local institutional review boards for Eli Lilly and the local institutional review boards for ADNI. Written informed consent was obtained from all participants or their assigned surrogate decision-makers prior to cohort enrollment.

: E.C., B.T., C.G., E.S. Y.P. report no competing interests.R.S. has received speaker honoraria from Roche and Triolab.S.P. has acquired research support (for the institution) from Avid and ki elements through ADDF. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Eli Lilly, Novo Nordisk, and Roche.M.P., V.K., I.K., and S.S. are employees and minor shareholders of Eli Lilly and Company.Research programs of W.F. have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, Avid, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF is recipient of TAP-dementia (), receiving funding from ZonMw (#10510032120003) in the context of Onderzoeksprogramma Dementie, part of the Dutch National Dementia Strategy. TAP-dementia receives co-financing from Avid Radiopharmaceuticals and Amprion. Gieskes-Strijbis fonds also contributes to TAP-dementia. WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funding is paid to her institution. WF is member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain.N.M.C. has received consultancy/speaker fees from Biogen, Merck, Owkin.O.H. is an employee of Lund University and Eli Lilly, and he has previously acquired research support (for Lund University) from AVID Radiopharmaceuticals, Biogen, C2 N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.E.vd.G. has performed contract research for Heuron Inc., AC Immune, and Roche. EvdG has a consultancy agreement with IXICO and Life Molecular Imaging for reading PET scans. All funding is paid to her institution.R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare and serves on advisory boards and/or steering committees for Asceneuron, Biogen, and Bristol Myers Squibb. All of the above is paid to his institutions.